Prognostic significance of systemic immune-inflammation index in patients with ovarian cancer: a meta-analysis

Abstract

BackgroundThe prognosis of several malignancies has been influenced by the systemic immune-inflammation index (SII); however, its association with the prognostic outcome of ovarian cancer (OC) remains controversial. The present meta-analysis focused on the systemic and comprehensive identification of the role of SII in predicting OC prognosis.MethodsWe searched the Web of Science, PubMed, Cochrane Library, Embase, and China National Knowledge Infrastructure (CNKI) from inception until March 6, 2023. To predict the prognostic value of SII for overall survival (OS) and progression-free survival (PFS) in patients with OC, we calculated pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs).ResultsThe meta-analysis included six studies involving 1546 patients. The combined results showed that a high SII was significantly associated with poor OS (HR=2.70, 95% CI=1.98–3.67, p<0.001) and poor PFS (HR=2.71, 95% CI=1.78–4.12, p<0.001) in OC patients. These results were confirmed using subgroup and sensitivity analyses.ConclusionOur results concluded that a high SII significantly predicted poor OS and PFS in patients with OC. Therefore, it can be speculated that the SII may have an independent effect on the prognosis of OC.

Unraveling the clinical significance and prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and delta neutrophil index

“…Several meta-analyses examining the predictive value of SII report similar results in gynecological cancers, breast cancers, ovarian cancer, prostate cancer, renal cell carcinoma, small-cell lung cancer, gastric cancer, biliary tract cancer, pancreatic carcinoma, and nasopharyngeal carcinoma with an HR of overall survival ranging between 1.32 and 2.71. [ 93 94 95 96 97 98 99 100 101 102 ] Conversely, SII was not found to be a significant predictor of progression-free survival in small-cell lung cancer, gastric cancer, and renal cell carcinoma in the same studies. [ 97 98 102 ]…”

Prognostic significance of C-reactive protein in patients with cervical cancer: a meta-analysis

“…I 2 was used to quantify the degree of heterogeneity among the studies, as follows: I 2 < 25%, low degree; 25–75%, moderate degree; and > 75%, high degree of heterogeneity ( 33 , 34 ). To analyze the pooled data, we used two different computational models, based on the traits of the included studies, and the cut-off for significant heterogeneity was set at I 2 > 50% ( 35 – 38 ). When high heterogeneity was determined based on I 2 > 50% and Q-test P < 0.10, and a random-effects model (REM; DerSimonian-Laird method) was used ( 39 ); otherwise, a fixed-effects model (FEM; Mantel-Haenszel method) was used ( 40 ).…”